

**INFORMATION DISCLOSURE
CITATION**Docket Number (Optional)
RDID 02010 USApplication Number
TBD

(Use several sheets if necessary)

Applicants(s)
Ghoshal et al.

Filing Date December 10, 2003

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Ref	Document Number	Date	Name	Class	Subclass	Filing Date (If Appropriate)
/SH/		5,633,405	5/27/97	Thompson et al.	564	321	

FOREIGN PATENT DOCUMENTS

Ref	Document Number	Date	Country	Class	Subclass	Translation

Other Documents (Including Author, Title, Date, Pertinent Pages, Etc.)

/SH/		Mutlib et al. "Identification and Characterization of Efavirenz Metabolites by Liquid Chromatography/Mass Spectrometry and High Field NMR: Species Differences in the Metabolism of Efavirenz". Drug Metabolism and Disposition, Vol 27, No. 11, pg 1319-1333 (1999)
		Marzolini et al., "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients". AIDS 2001, 15: 71-75
		Singh et al., "Cesium Fluoride Catalyzed Trifluoromethylation of Esters, Aldehydes, and Ketones with (Trifluoromethyl) Trimethylsilane", J. Org Chem 1999, 64, 2873-2876
		Radesca, et al., "Synthesis of HIV-1 Reverse Transcriptase Inhibitor DMP 266", Synthetic Communications, 27(24), 4373-4384 (1997)
		Zhuyin Li et al., "New Synthesis and Characterization of (+) Lysergic Acid Diethylamide (LSD) Derivatives and the Development of a Microparticle-Based Immunoassay for the Detection of LSD and Its Metabolites", Bioconjugate Chem. 1997, 8, 896-905
		Prakash, G.K., Yudin AK, "Perfluoroalkylation with Organosilicon Reagents", Chem Rev 1997, 97, 757-786
↓		Patel, et al., "Synthesis and Evaluation of Analogs of Efavirenz (Sustiva™) as HIV-1 Reverse Transcriptase Inhibitors", Bioorganic & Medicinal Chemistry Letters 9 (1999), 2805-2810

Examiner /Shafiquel Haq/

Date Considered 09/11/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**